Spike proteins on the surface of human corona viruses is important to enhance it’s competency to get transmit into other healthy population. Because of it’s specific spike protein, the virus got its name corona in 1960s. Afterward, it was renamed as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2002 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012. It was mortal for old population, new born babies and immune-compromised individuals, who didn't have sufficient immunity or defense system. On February 11, 2020, World Health Organization (WHO) gave the names of COVID-19 and SARS-CoV-2. A characteristic of nCoV-19, which is a cause of COVID-19, was identified as major cause of pneumonia. However, the healthcare professionals worked hard to to stop it’s outbreak and transmission all over the world. But, there was no medicines that have been cleared by the FDA to treat COVID-19 successfully. So, the goal of this study is to look at the scientific data that is already available about clinical care and therapy of this disease. Some of the sources that were checked for this study were BioRxiv, medRxiv, Google Scholar, Embase, PsychINFO, WanFang Data, and PubMed. A lot of work went into finding out what medicines could be used to avoid and treat COVID-19 illnesses. Remdesivir, chloroquine, hydroxychloroquine, and immunosuppressant drugs have all been shown to help to fight the virus. Until a treatment for the COVID-19 virus is found, it is best to stay away from other people and follow strict hygiene. Most medicinal treatments still have a lot of unknown effects, and different medicines and vaccines are being trialed and tested succefully to stop prevelance, transmission and develop the symptoms.

Keywords: COVID-19; Virology; Vaccine entities; Pharmacotherapy; Nanotechnology